Loading...
XNAS
SIBN
Market cap749mUSD
Jul 10, Last price  
17.56USD
1D
3.14%
1Q
35.67%
IPO
-17.05%
Name

SI-BONE Inc

Chart & Performance

D1W1MN
XNAS:SIBN chart
P/E
P/S
3.88
EPS
Div Yield, %
Shrs. gr., 5y
8.41%
Rev. gr., 5y
22.32%
Revenues
201m
+20.19%
37,016,00048,999,00040,054,00041,173,00042,101,00047,983,00055,380,00067,301,00073,387,00090,152,000106,409,000138,886,000167,178,000200,926,000
Net income
-19m
L-38.83%
-10,903,000-6,154,000-27,806,000-28,154,000-20,589,000-23,039,000-17,453,000-38,403,000-43,697,000-56,572,000-61,256,000-43,336,000-30,913,000-18,908,000
CFO
-675k
L-94.57%
-14,759,000-566,000-26,327,000-26,718,000-16,753,000-17,530,000-14,519,000-31,627,000-30,662,000-39,533,000-41,655,000-18,713,000-12,425,000-675,000
Earnings
Aug 03, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
IPO date
Oct 17, 2018
Employees
357
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT